Proof Diagnostics develops a portable diagnostic system utilizing CRISPR-based and OMEGA RNA programmable technologies for the rapid detection of infectious diseases such as SARS-CoV-2, Flu A/B, and RSV. This system addresses the need for low-cost, sensitive, and easy-to-use diagnostics in both clinical and at-home settings.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional diagnostic methods for infectious diseases often require specialized laboratory equipment and trained personnel, leading to delays in diagnosis and limited accessibility, especially in resource-constrained settings or for point-of-care applications. Existing diagnostic tools may also lack the sensitivity needed for early detection of certain pathogens.
Solution
Proof Diagnostics developed a portable diagnostic system that leverages CRISPR-based and OMEGA RNA programmable technologies for rapid and sensitive detection of infectious diseases, including SARS-CoV-2, Flu A/B, and RSV. The system is designed to be low-cost and easy to use, enabling deployment in both clinical and at-home settings. The core innovation lies in the use of OMEGA enzymes, which are smaller and more robust than traditional CRISPR Cas enzymes, facilitating easier delivery and potentially opening new therapeutic avenues.
Target Audience
The primary target audience includes healthcare providers, clinical laboratories, and individuals seeking rapid and accessible diagnostic solutions for infectious diseases.
Features
- Utilizes CRISPR-based and OMEGA RNA programmable technologies for pathogen detection.
- Designed for rapid results, enabling timely clinical decisions.
- Portable system allows for point-of-care and at-home testing.
- Aims for high sensitivity to detect low viral loads.
- Intended to be low-cost for broad accessibility.
- Easy-to-use design minimizes the need for specialized training.